AI Article Synopsis
- New vaccine products for invasive pneumococcal disease (IPD) were authorized in Canada, prompting a study to examine trends in IPD incidence and severity in Ontario across different time periods, including pre- and post-vaccine introduction and during the COVID-19 pandemic.
- The analysis revealed a decline in IPD incidence and hospitalizations among children under 5 years after the introduction of the 13-valent vaccine (PCV13), but an increase in case fatality rates and hospitalizations among older adults.
- Despite the overall decrease in cases from PCV13 serotypes, there was a rise in cases from newer serotypes, highlighting the need for ongoing surveillance and possible adjustments to vaccination strategies.
Article Abstract
Background: New vaccine products were recently authorized for protection against invasive pneumococcal disease (IPD) in Canada. Our aim was to determine age- and serotype-specific trends in IPD incidence and severity in Canada's largest province, Ontario.
Methods: We included all confirmed IPD cases reported in Ontario and defined the pre-pneumococcal 13-valent conjugate vaccine (PCV13) era (01/2007 to 12/2010), post-PCV13 era (01/2011 to 12/2019), and coronavirus disease 2019 (COVID-19) pandemic era (01/2020 to 12/2022). We estimated incidence, hospitalization, and case fatality rate (CFR) by age. We grouped IPD cases by vaccine-specific serotypes (PCV13; PCV15-non-PCV13; PCV20-non-PCV13; PCV20-non-PCV15; polysaccharide 23-valent vaccine-non-PCV20; and non-vaccine-preventable [NVP]). We then compared incidence rates by age and serotype group in the pre- and post-PCV13 eras by calculating rate ratios (RRs) and their 95% CIs.
Results: Incidence and hospitalizations declined from the pre- to post-PCV13 era in children aged <5 years (RR, 0.7; 95% CI, 0.6-0.8; and RR, 0.8; 95% CI, 0.7-0.9, respectively), but the CFR increased (1.4% to 2.3%). Other age groups saw smaller declines or more stable incidence rates across the years; hospitalizations increased in adults aged 50-64 years (RR, 1.2; 95% CI, 1.1-1.4) and ≥65 years (RR, 1.1; 95% CI, 1.0-1.1). For all ages, IPD cases and hospitalizations attributable to PCV13 serotypes declined, and those attributable to PCV15-non-PCV13, PCV20-non-PCV13, and NVP serotypes increased. IPD incidence declined during the COVID-19 era.
Conclusions: IPD incidence and hospitalizations due to PCV13 serotypes decreased after PCV13 introduction but increased for other serotypes. Continued surveillance is required to evaluate changes to pneumococcal vaccination programs and ongoing changes to the distribution of IPD-causing serotypes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11167672 | PMC |
| http://dx.doi.org/10.1093/ofid/ofae275 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Simplified process for preparing native and depolymerized capsular polysaccharides of Streptococcus pneumoniae.
Carbohydr Polym
March 2025
Beijing Minhai Biotechnology Co. Ltd, Beijing 102600, China. Electronic address:
Streptococcus pneumoniae is a major pathogen of bacterial pneumonia, meningitis, sepsis, and otitis media. The pathogenicity of this bacterium is largely attributed to its polysaccharide capsule, a protective layer around bacterial cell that enables bacteria to resist against host defense. Capsular polysaccharides (CPSs) of S.
View Article and Find Full Text PDFA comprehensive analysis of serotype-specific invasive capacity, clinical presentations, and mortality trends of invasive pneumococcal disease.
Vaccine
January 2025
Department of Pediatrics, Section of Infectious Diseases and Global Health, Yale University School of Medicine, New Haven, CT, United States; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States; Yale Institute for Global Health, Yale University, New Haven, CT, United States; Yale Center for Infection and Immunity, Yale University, New Haven, CT, United States. Electronic address:
Background: Pneumococcal conjugate vaccines (PCV) reduced invasive disease, but the overall prevalence of pneumococcal nasopharyngeal colonization among children has not changed significantly. Our knowledge of which serotypes, once colonized, hold a higher likelihood to cause invasive disease is limited.
Methods: Serotype-specific invasive capacity (IC) of Streptococcus pneumoniae was estimated using an enhanced population-based invasive pneumococcal disease (IPD) surveillance in children <7 years of age in Massachusetts and surveillance of nasopharyngeal (NP) colonization in selected Massachusetts communities in corresponding respiratory seasons.
Weakened Airway Epithelial Junctions and Enhanced Neutrophil Elastase Release Contribute to Age-Dependent Bacteremia Risk Following Pneumococcal Pneumonia.
Aging Cell
January 2025
Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA.
Streptococcus pneumoniae (Sp; pneumococcus), the most common agent of community-acquired pneumonia, can spread systemically, particularly in the elderly, highlighting the need for adjunctive therapies. The airway epithelial barrier defends against bacteremia and is dependent upon apical junctional complex (AJC) proteins such as E-cadherin. After mouse lung challenge, pneumolysin (PLY), a key Sp virulence factor, stimulates epithelial secretion of an inflammatory eicosanoid, triggering the infiltration of polymorphonuclear leukocytes (PMNs) that secrete high levels of neutrophil elastase (NE), thus promoting epithelial damage and systemic infection.
View Article and Find Full Text PDFPost-pandemic epidemiological trends of respiratory infectious diseases in Taiwan: A retrospective analysis.
J Microbiol Immunol Infect
December 2024
Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan. Electronic address:
Background: This study analyzed the epidemiological trends of three significant respiratory infectious diseases in Taiwan: invasive pneumococcal disease (IPD), influenza with severe complications, and tuberculosis during post-COVID-19 pandemic period.
Methods: We utilized data from Taiwan's Centers for Disease Control and Prevention (CDC) website and classified the COVID-19 prevention policies into three phases for the year 2021, 2022, and 2023. We then performed a statistical analysis of reported case numbers for the three respiratory diseases during the 3-year period using the Kruskal-Wallis test, followed by joinpoint regression model for the identification of seasonal distribution and variation.
[Chinese expert consensus on the diagnosis and treatment of pneumonia in the elderly (2024 Edition)].
Zhonghua Jie He He Hu Xi Za Zhi
January 2025
China is experiencing a demographic shift as its population ages. The elderly population becomes increasingly susceptible to pneumonia. Pneumonia in the elderly is characterized by its insidious onset, rapid progression, multiple comorbidities, poor prognosis, and high morbidity and mortality.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!